Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

Please provide your email address to receive an email when new articles are posted on . Even with algorithms available, dosing for Mircera appears to vary widely among nephrologists. Dialysis clinics ...

A pivotal study published today in the Lancet has shown that dialysis patients can be effectively switched from frequently dosed anaemia drugs to an innovative new anaemia treatment, MIRCERA, that can ...

-- First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi-centre renal anaemia study show that switching patients directly from frequent ...

New data for Roche’s anaemia drug Mircera confirm that the drug can raise haemoglobin levels in the blood with twice-monthly dosing, suggesting it will mount a strong challenge to current treatments ...

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

maintained Hb levels as effectively as more frequently-dosed ESAs, in patients with the lowest baseline Hb who are difficult to treat. - In the correction studies, the mean baseline low Hb in the ...

The judge refereeing the turf battle between Roche and Amgen over anemia meds has taken a time-out to consult the experts. Judge William Young said he's grappling "with complex issues" in the patent ...

NUTLEY, N.J., Nov. 14 Roche announced today that the U.S. Food and Drug Administration (FDA) has approved MIRCERA (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia associated with ...

three times a week for the maintenance treatment of anaemia. The study results showed: - Minute changes in patients' haemoglobin (Hb) levels from baseline to evaluation (-0.131g/dL for MIRCERA once ...